What's in UBI Pharma Inc.'s pipeline?

UBI Pharma Inc. has 2 drugs in our index: 1 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with UBI Pharma Inc.'s portfolio?

Top competitors by shared drug class: ADvantage Therapeutics, AJU Pharm Co., Ltd., AO GENERIUM, Abbott, AceLink Therapeutics, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/ubi-pharma-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

UBI Pharma Inc. — Portfolio Competitive Intelligence Brief

UBI Pharma Inc. pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Eprex	Eprex	marketed			Other
UB-851	UB-851	phase 3	SGLT2 inhibitor	SGLT2	Diabetes

Therapeutic area mix

Diabetes · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

ADvantage Therapeutics · 1 shared drug class
AJU Pharm Co., Ltd. · 1 shared drug class
AO GENERIUM · 1 shared drug class
Abbott · 1 shared drug class
AceLink Therapeutics, Inc. · 1 shared drug class
Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
Aciex Therapeutics, Inc. · 1 shared drug class
3D Medicines (Beijing) Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for UBI Pharma Inc.:

Cite this brief

Drug Landscape (2026). UBI Pharma Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ubi-pharma-inc. Accessed 2026-05-14.